Shares of Alexion Pharmaceuticals, Inc. (ALXN) are currently surging over 30% after AstraZeneca agreed to acquire the company.
ALXN is currently trading at $157.77, up $36.79 or 30.41%, on the Nasdaq.
AstraZeneca will pay around $175 per share for Alexion, through a combination of cash and shares, valuing the Boston-based group at $39 billion. This represents about 45% premium to Alexion's Friday closing price.
Alexion shareholders will own around 15% of AstraZeneca's outstanding shares when the deal closes in the third quarter of next year.
Alexion lifted its 2020 revenue guidance in October, and set a 2025 target of between $9 billion and $10 billion in annual sales.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.